| General Information | |
|---|---|
| ZINC ID | ZINC000069831354 |
| Molecular Weight (Da) | 281 |
| SMILES | O=C(C1C2CC3CC(C2)CC1C3)N1CCc2ccccc21 |
| Molecular Formula | C19N1O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 83.063 |
| HBA | 1 |
| HBD | 0 |
| Rotatable Bonds | 1 |
| Heavy Atoms | 21 |
| LogP | 3.749 |
| Activity (Ki) in nM | 7.079 |
| Polar Surface Area (PSA) | 20.31 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | - |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.7887234 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.63 |
| Ilogp | 3.12 |
| Xlogp3 | 4.34 |
| Wlogp | 3.27 |
| Mlogp | 4.08 |
| Silicos-it log p | 3.28 |
| Consensus log p | 3.62 |
| Esol log s | -4.4 |
| Esol solubility (mg/ml) | 1.12E-02 |
| Esol solubility (mol/l) | 4.00E-05 |
| Esol class | Moderately |
| Ali log s | -4.48 |
| Ali solubility (mg/ml) | 9.29E-03 |
| Ali solubility (mol/l) | 3.30E-05 |
| Ali class | Moderately |
| Silicos-it logsw | -3.85 |
| Silicos-it solubility (mg/ml) | 4.01E-02 |
| Silicos-it solubility (mol/l) | 1.43E-04 |
| Silicos-it class | Soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.94 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 4.46 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.847 |
| Logd | 3.963 |
| Logp | 4.616 |
| F (20%) | 0.004 |
| F (30%) | 0.012 |
| Mdck | 4.62E-05 |
| Ppb | 0.8701 |
| Vdss | 1.291 |
| Fu | 0.0182 |
| Cyp1a2-inh | 0.133 |
| Cyp1a2-sub | 0.806 |
| Cyp2c19-inh | 0.832 |
| Cyp2c19-sub | 0.677 |
| Cl | 8.46 |
| T12 | 0.029 |
| H-ht | 0.162 |
| Dili | 0.659 |
| Roa | 0.065 |
| Fdamdd | 0.013 |
| Skinsen | 0.061 |
| Ec | 0.004 |
| Ei | 0.104 |
| Respiratory | 0.183 |
| Bcf | 3.587 |
| Igc50 | 4.519 |
| Lc50 | 5.384 |
| Lc50dm | 6.104 |
| Nr-ar | 0.029 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.257 |
| Nr-aromatase | 0.864 |
| Nr-er | 0.276 |
| Nr-er-lbd | 0.225 |
| Nr-ppar-gamma | 0.007 |
| Sr-are | 0.401 |
| Sr-atad5 | 0.003 |
| Sr-hse | 0.495 |
| Sr-mmp | 0.73 |
| Sr-p53 | 0.164 |
| Vol | 303.639 |
| Dense | 0.926 |
| Flex | 23 |
| Nstereo | 0.087 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 0 |
| Qed | 3 |
| Synth | 0.769 |
| Fsp3 | 3.501 |
| Mce-18 | 0.632 |
| Natural product-likeness | 66.581 |
| Alarm nmr | -0.668 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Rejected |